Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic

Fig. 2

Occurrence of AEs ≥ Grade 3 after administration of ICI and changes in incidence of AEs ≥ Grade 3 over time after administration. In Japan, the number of COVID- 19 cases peaked in 2022, and COVID- 19 vaccination was initiated in April 2021. The history of ICI approvals in Japan is shown in Supplementary Table 2. Monthly percentage of patients with AEs ≥ Grade 3 after treatment with ICI, and the number of AEs in each category: 1. Blue: respiratory disorders. 2. Green: hepatobiliary disorders. 3. Red: cardiac and vascular disorders. 4. Brown: gastrointestinal disorders. 5. Yellow: endocrine disorders. 6. Purple: neuromuscular disorders. 7. Beige: skin disorders. 8. Pink: blood and lymphatic system disorders. 9. Light blue: renal disorders. 10. Gray: other disorders

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us